National Burden of Preventable Adverse Drug Events Associated with Inpatient Injectable Medications: Healthcare and Medical Professional Liability Costs
Betsy J Lahue, MPH, Bruce Pyenson, FSA, MAAA, Kosuke Iwasaki, FIAJ, MAAA, Helen Blumen, MD, MBA, Susan Forray, FCAS, MAAA, Jeffrey M. Rothschild, MD, MPH
Preventable medication errors have emerged as a prominent cost and quality issue in the United States, and are estimated to impact more than 7 million patients, contribute to 7000 deaths, and cost almost $21 billion in direct medical costs across all care settings annually.1,2 Adverse drug events (ADEs) are harms that result from medication use; when these harms result from a medication error, they are known as “preventable ADEs.”3 The inpatient hospital setting is particularly resource-intensive in terms of care delivered and exposure to potential harms a
President Obama’s victory in November resolves whether the Affordable Care Act (ACA) will be implemented. In general terms, it will. Although the Republican-controlled House of Representatives may pass another resolution to abolish the ACA, that threat is not credible, with Democrats in charge in the Senate. But that does not settle what will actually become of the law.
According to Michael Kleinrock, Director of Research Development at the IMS Institute, breakthrough therapies, innovation in disease treatments, and changes in the consumption of medicines transformed the US healthcare market in 2011.1 At the core of this interesting report are 5 takeaway messages1:
Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets
Anke-Peggy Holtorf, PhD, MBA, Diana Brixner, RPh, PhD, Brandon Bellows, PharmD, Abdulkadir Keskinaslan, MD, MBA, MPH, Joseph Dye, RPh, PhD, Gary Oderda, PharmD, MPH
With increasing access and utilization of healthcare, resources become more restricted, and prioritization in healthcare becomes unavoidable. Health economics and outcomes research (HEOR) is a discipline that is used to complement traditional clinical development information (ie, efficacy, safety, quality) to guide decision makers regarding patient access to specific drugs and services. HEOR has advanced considerably in methodology and in quantity over the past several decades.
Health Economics and Outcomes Research Data Key in Coverage Decisions of New Medications
Value-based reimbursement represents a fundamental shift in the way health plans pay providers for care. Rather than creating incentives for providers to deliver high-quantity care—a downside of the fee-for-service (FFS) model—value-based reimbursement aims at creating incentives for providers to achieve high-quality care.1,2 Because value-based reimbursement is focused on driving healthcare value, improved population-based outcomes are an expected result.1,2
Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care
Annette Powers, PharmD, MBA, Claudio Faria, PharmD, MPH, Eunice Chang, PhD, Dasha Cherepanov, PhD, Jeffrey A. Bourret, PharmD, MS, BCPS, FASHP
Myelodysplastic syndrome (MDS) encompasses a heterogeneous group of clonal disorders of hematopoiesis and is characterized by dysplastic morphology of marrow and blood cells, ineffective hematopoiesis, and peripheral blood cytopenias.1,2 Most patients with MDS experience progressive worsening of blood cytopenias, with an increasing need for transfusion.2 These patients also have an increasing number of potentially fatal infections and hemorrhagic complications.2 The more advanced and severe the MDS is, the greater the risk that the disease will progress to a
Reconsidering the Management of Younger Patients with Myelodysplastic Syndrome
Results 1 - 8 of 8